Adverse outcome pathways: opportunities, limitations and open questions

Marcel Leist, Ahmed Ghallab, Rabea Graepel, Rosemarie Marchan, Reham Hassan, Susanne Hougaard Bennekou, Alice Limonciel, Mathieu Vinken, Stefan Schildknecht, Tanja Waldmann, Erik Danen, Ben van Ravenzwaay, Hennicke Kamp, Iain Gardner, Patricio Godoy, Frederic Y. Bois, Albert Braeuning, Raymond Reif, Franz Oesch, Dirk DrasdoStefan Höhme, Michael Schwarz, Thomas Hartung, Thomas Braunbeck, Joost Beltman, Harry Vrieling, Ferran Sanz, Anna Forsby, Domenico Gadaleta, Ciarán Fisher, Jens Kelm, David Fluri, Gerhard Ecker, Barbara Zdrazil, Andrea Terron, Paul Jennings, Bart van der Burg, Steven Dooley, Annemarie H. Meijer, Egon Willighagen, Marvin Martens, Chris Evelo, Enrico Mombelli, Olivier Taboureau, Alberto Mantovani, Barry Hardy, Bjorn Koch, Sylvia Escher, Christoph van Thriel, Cristina Cadenas, D. Kroese, Bob van de Water, Jan G. Hengstler

Research output: Contribution to journalArticlepeer-review

153 Scopus citations

Fingerprint

Dive into the research topics of 'Adverse outcome pathways: opportunities, limitations and open questions'. Together they form a unique fingerprint.

Chemical Compounds

Medicine & Life Sciences